Pulsatile Drug Delivery Systems are gaining a lot of interest as they deliver the drug at the right place at the right time and in the right amount, thus providing spatial, temporal and smart delivery and increasing patient compliance. These systems are designed according to the biological rhythm of the body. Here drug delivery is facilitated according to disease rhythm. The principle rationale for the use of pulsatile release of the drugs is where a constant drug release is not desired. A pulse has to be designed in such a way that a complete and rapid drug release is achieved after the lag time. Various systems like capsular systems, osmotic systems, single and multiple-unit systems based on the use of soluble or erodible polymer coating and use of rupturable membranes have been dealt with in the article. These systems are beneficial for the drugs having chronopharmacological behavior such as drug used in treatment of rheumatoid arthritis, osteo arthritis and ankylosing spondylitis like inflammatory disorders. Current review article discussed the reasons for development of pulsatile drug delivery system, types of the disease in which pulsatile release is required, classification, advantages, and limitation, of pulsatile drug delivery system.
time (an interval of no drug release) has to be designed in such a way that a complete and rapid drug release follows the lag time. In chronopharmacotherapy(timed drug therapy) drug administration is synchronized with biological rhythms to produce maximal therapeutic effect and minimum harmfor the patient.Pulsatile release is also useful for the targeting of the drug irritating the stomach or degradable therein, as well for drugs developing biological tolerance or with an extensive first pass metabolism. 
Drug release profile of pulsatile drug delivery systems

NECESSITY OF PULSATILE DRUG DELIVERY SYSTEMS
There are many conditions and diseases where sustained release formulations do not show good efficacy. In such cases Pulsatile DDS is applicable.
First pass metabolism
Some drugs, such as beta blockers, and salicylamide, undergo extensive first pass Metabolism and require fast drug input to saturate metabolizing enzymes in order to minimize pre-systemic metabolism. Thus, a constant/sustained oral method of delivery would result in reduced oral bioavailability9.
Biological tolerance
Drug plasma profiles are often accompanied by a decline in the pharmacotherapeutic effect of the drug, e.g., biological tolerance of transdermal nitroglycerin, salbutamol sulphate.
Special chronopharmacological needs
Circadian rhythms in certain physiological functions are well established. It has been recognized that many symptoms and onset of disease occur during specific time periods of the 24 hour day, e.g., asthma and angina pectoris attacks are most frequently in the morning hours.
Local therapeutic need
For the treatment of local disorders such as inflammatory bowel disease, inflammation with no loss due to absorption in the small intestine is highly desirable to achieve the therapeutic effect and to minimize side effects. Advantages of the Pulsatile drug delivery systems:
1. These systems can be used for extended day time or night time activity.
2. They reduce the dose frequency, dose size and cost, which ultimately reduce side effects, thereby improving patient compliance.
3. Hormones such as renin, aldosterone, and cortisol etc. their levels in blood may alter with circadian rhythms therefore drug delivery through this system suits circadian rhythms of body functions or diseases.
4. Drug targeting to a specific site, like the colon (in case of ulcerative colitis) can be achieved.
5. This system helps to prevent the continuous presence of some drugs (e.g. salbutamol sulphate) that produce biological tolerance and thus they increase their therapeutic effect.
6. These systems are beneficial for the drugs having chronopharmacological behavior where night time dosing is required and for the drugs having high firstpass effect.
7. They provide constant drug levels at the site of action and prevent the peak-valley fluctuations.
8. Protection from gastric environment is essential for drugs that cause gastric irritation (e.g. NSAIDS) or get degraded in gastric medium (e.g. peptide drugs) so enteric coated Pulsatile drug delivery system can be the best option for it.
Limitations
1. Multiple manufacturing steps in case of Multiparticulate drug delivery system.
2. Low drug loading capacity and incomplete release of drug.
3. In vivo variability in single unit pulsatile drug delivery system.
4. Drug dose manipulation in case of child and elder patients is not possible.
Immediate withdrawal of drug is not possible.
Classification
Methodologies for the PDDS can be broadly classified into four classes;
www.wjpps.com and a modulating agent, sodium chloride (NaCl). The amount of NaCl was such that it was less than the amount needed to maintain saturation in a fluid that enters the osmotic device.
The pulsed delivery is based on drug solubility. The modulating agent can be a solid organic acid, inorganic salt, or organic salt.
 A System Based on Expandable Orifice: This device is in the form of capsule from which the drug is delivered by the capsule's osmotic infusion of moisture from the body.
There is an orifice consisting of elastic material on the capsule's wall. It is so small that under relaxed condition flow of the drug through the orifice is nearly zero. When the pressure is developed inside the shell elastic wall is stretched. Consequently the orifice expands sufficiently from time to time to allow the release of drug in pulsatile manner.
Delivery by Reservoir Systems with Erodible or Soluble Barrier Coatings:
In such systems the drug release is controlled by the dissolution or erosion of the outer coat which is applied on the core containing drug. Time dependent release of the active ingredient can be obtained by optimizing the thickness of the outer.
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These systems are another class of reservoir type pulsatile systems with a barrier layer, whichdissolves or erodes after a specific ag time followed by burst release of drug from the reservoir core. Generally in these , the lag time is controlled by thickness of coating layer.
For instance, a chronotropic system which consists of a drug containing core layered with HPMC and a top layer of enteric coating, the lag time before drug release will be dependent upon the thickness and viscosity grade of HPMC layer. Since drug release mechanism in these types of systems is dissolution, that"s why, a high degree of drug solubility relative to dose of drug is essential for rapid release of drug after the lag period. 
Delivery System with Soluble or Erodible
III. Chemical stimuli induced pulsatile systems
This system was divided into three subparts and is discussed below.
A. Glucose-responsive Insulin Release Devices
There has been much interest in the development of stimuli-sensitive delivery system that releases therapeutic agents in presence of specific enzyme or protein. This pHchange induces swelling of the polymer which results in insulin release. Insulin by virtue of its action reduces blood glucose level and consequently gluconic acid level also gets decreased and system turns to the deswelling mode thereby decreasing the insulin release.
B. Drug release from intelligent gels responding to antibody concentration
There are numerous kinds of bioactive compounds which exist in the body. Recently, novel gels were developed which responded to the change in concentration of bioactive compounds to alter their swelling/deswelling characteristics. Special attention was given to antigenantibody complex formation as the cross-linking units in the gel, since such interaction is very specific. The difference in association constants between polymerized antibodies and naturally derived antibodies towards specific antigens reversible gel swelling/deswelling and drug permeation changes occurs.
IV. External stimuli Pulsatile release
This system was divided into three subparts and is discussed below. consists of an array of reservoirs that extend through an electrolyte-impermeable substrate.
The prototype microchip is made of silicon and contains a number of drug reservoirs; each reservoir is sealed at one end by a thin gold membrane of material that serves as an anode in an electrochemical reaction and dissolves when an electric potential is applied to it in an electrolyte solution. The reservoirs are filled with any combination of drug or drug mixtures in any form (i.e. solid, liquid or gel). When release is desired, an electric potential is applied between an anode membrane and a cathode, the gold membrane anode dissolves within [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] seconds and allows the drug in the reservoir to be released. This electric potential causes oxidation of the anode material to form a soluble complex with the electrolytes which then dissolves allowing release of the drug. Complex release patterns (such as simultaneous constant and pulsatile release) can be achieved from the microchips. Microchip has the ability to control both release time and release rate.
B. Magnetically Induced Pulsatile Release.
Use of an oscillating magnetic to regulate the drug delivery from a polymer matrix was one of the first methodologies investigated to develop an externally controlled drug delivery system. Magnetic carriers receive a response to a magnetic field from incorporated materials such as magnetite, iron, nickel, cobalt, etc. For biomedical applications, magnetic carriers must be water-based, biocompatible, non-toxic and non-immunogenic. Basically the mechanistic approach behind the strategy is based on the slowing down the movement of oral drugs in the gastrointestinal system through magnetic attraction. The speed of travel through the stomach and intestines can then be slowed down at specific positions by an external magnet, thus changing the timing and/or extent of drug absorption into stomach or intestine.
C. Electro Responsive Pulsatile Release
The combination of developments in several technologies, such as microelectronics and micromachin ing, as well as the potential need for chronotherapy, have currently assisted the development of electronically assisted drug delivery technologies. These technologies include iontophoresis, infusion pumps, and sonophoresis. They utilized a chemomechanical system,
